F8 and hemophilia: These participants also reported that they had identified an important generational change in the treatment of hemophilia, as most of them received cryoprecipitates and plasma FVIII as early treatments, and the current generation of drugs offered more benefits in terms of bleeding prevention, reduction of the consequences and impact on HRQoL.